Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Cao, Long Hui ^a   Li, Hui Ting ^a   Lin, Wen Qian ^a   Tan, Hong Ying ^a   Xie, Lan ^a   Zhong, Zhong Jian ^a   Zhou, Jian Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CISPLATIN; MORPHINE; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MOUSE; NASOPHARYNGEAL NEOPLASMS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; GENE EXPRESSION; HUMANS; MICE; MICE, NUDE; MORPHINE; NASOPHARYNGEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84953295479     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18706     Document Type: Article

References (59)

1. McDermott, A. L., Dutt, S. N. & Watkinson, J. C. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci. 26, 82-92 (2001).
2. Cheng, S. H. et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol. 18, 2040-2045 (2000).
3. Serin, M., Erkal, H. S. & Cakmak, A. Radiation therapy and concurrent cisplatin in management of locoregionally advanced nasopharyngeal carcinomas. Acta Oncol 38, 1031-1035 (1999).
4. Epstein, J. B. & Jones, C. K. Presenting signs and symptoms of nasopharyngeal carcinoma. Oral Surg Oral Med Oral Pathol 75, 32-36 (1993).
5. Huang, H. Y., Wilkie, D. J., Schubert, M. M. & Ting, L. L. Symptom profile of nasopharyngeal cancer patients during radiation therapy. Cancer Pract 8, 274-281 (2000).
6. Huang, H. Y., Wilkie, D. J., Chapman, C. R. & Ting, L. L. Pain trajectory of Taiwanese with nasopharyngeal carcinoma over the course of radiation therapy. J Pain Symptom Manage 25, 247-255 (2003).
7. Janjan, N. A., Weissman, D. E. & Pahule, A. Improved pain management with daily nursing intervention during radiation therapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys 23, 647-652 (1992).
8. Porter, A. G., Ng, P. & Janicke, R. U. Death substrates come alive. Bioessays 19, 501-507, doi: 10.1002/bies.950190609 (1997).
9. Murata, T., Hibasami, H., Maekawa, S., Tagawa, T. & Nakashima, K. Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells. Biochem Int 20, 949-955 (1990).
10. Olivero, O. A., Semino, C., Kassim, A., Lopez-Larraza, D. M. & Poirier, M. C. Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. Mutat Res 346, 221-230 (1995).
11. Cilenti, L. et al. Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am J Physiol Renal Physiol 288, F371-379, doi: 10.1152/ajprenal.00154.2004 (2005).
12. Tegeder, I. & Geisslinger, G. Opioids as modulators of cell death and survival - unraveling mechanisms and revealing new indications. Pharmacol Rev 56, 351-369, doi: 10.1124/pr.56.3.2 (2004).
13. Singhal, P. C. et al. Morphine enhances macrophage apoptosis. J Immunol 160, 1886-1893 (1998).
14. Tegeder, I. et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res 63, 1846-1852 (2003).
15. Oliveira, M. T., Rego, A. C., Macedo, T. R. & Oliveira, C. R. Drugs of abuse induce apoptotic features in PC12 cells. Ann N Y Acad Sci. 1010, 667-670 (2003).
16. Mao, J., Sung, B., Ji, R. R. & Lim, G. Neuronal apoptosis associated with morphine tolerance: evidence for an opioid-induced neurotoxic mechanism. J Neurosci 22, 7650-7661 (2002).
17. Kim, M. S. et al. Protective effects of morphine in peroxynitrite-induced apoptosis of primary rat neonatal astrocytes: potential involvement of G protein and phosphatidylinositol 3-kinase (PI3 kinase). Biochem Pharmacol 61, 779-786 (2001).
18. Gupta, K. et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 62, 4491-4498 (2002).
19. Ishikawa, M., Tanno, K., Kamo, A., Takayanagi, Y. & Sasaki, K. Enhancement of tumor growth by morphine and its possible mechanism in mice. Biol Pharm Bull 16, 762-766 (1993).
20. Cory, S. & Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2, 647-656, doi: 10.1038/nrc883 (2002).
21. Farooqui, M. et al. Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Mol Cancer Ther 5, 611-620, doi: 10.1158/1535-7163.MCT-05-0016 (2006).
22. Singleton, P. A., Lingen, M. W., Fekete, M. J., Garcia, J. G. & Moss, J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res 72, 3-11, doi: 10.1016/j.mvr.2006.04.004 (2006).
23. Vincent, L. et al. Mast cell activation contributes to sickle cell pathobiology and pain in mice. Blood 122, 1853-1862, doi: 10.1182/blood-2013-04-498105 (2013).
24. Kampa, M. et al. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur J Pharmacol 335, 255-265 (1997).
25. Maneckjee, R., Biswas, R. & Vonderhaar, B. K. Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res 50, 2234-2238 (1990).
26. Maneckjee, R. & Minna, J. D. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci USA 87, 3294-3298 (1990).
27. Qin, Y. et al. Exogenous morphine inhibits human gastric cancer MGC- 803 cell growth by cell cycle arrest and apoptosis induction. Asian Pac J Cancer Prev 13, 1377-1382 (2012).
28. Lewis, J. W. et al. Apparent involvement of opioid peptides in stress-induced enhancement of tumor growth. Peptides 4, 635-638 (1983).
29. Simon, R. H. & Arbo, T. E. Morphine increases metastatic tumor growth. Brain Res Bull 16, 363-367 (1986).
30. Sergeeva, M. G., Grishina, Z. V. & Varfolomeyev, S. D. Morphine effect on proliferation of normal and tumor cells of immune origin. Immunol Lett 36, 215-218 (1993).
31. Al-Sarraf, M. et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16, 1310-1317 (1998).
32. McQuay, H. J. et al. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clinical pharmacology and therapeutics 48, 236-244 (1990).
33. Klepstad, P., Kaasa, S. & Borchgrevink, P. C. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. European journal of clinical pharmacology 55, 713-719 (2000).
34. Roy, S., Cain, K. J., Chapin, R. B., Charboneau, R. G. & Barke, R. A. Morphine modulates NF kappa B activation in macrophages. Biochemical and biophysical research communications 245, 392-396, doi: 10.1006/bbrc.1998.8415 (1998).
35. Zech, D. F., Grond, S., Lynch, J., Hertel, D. & Lehmann, K. A. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 63, 65-76 (1995).
36. Davis, M. P., Walsh, D., Lagman, R. & LeGrand, S. B. Controversies in pharmacotherapy of pain management. Lancet Oncol 6, 696-704, doi: 10.1016/S1470-2045(05)70317-X (2005).
37. Ryan, M., Moynihan, T. J. & Loprinzi, C. L. As-needed morphine: yes, but at what dose and at what interval? J Clin Oncol 23, 3849-3852, doi: 10.1200/JCO.2005.02.360 (2005).
38. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
39. Hengartner, M. O. The biochemistry of apoptosis. Nature 407, 770-776, doi: 10.1038/35037710 (2000).
40. Parsons, M. J. & Green, D. R. Mitochondria in cell death. Essays Biochem 47, 99-114, doi: 10.1042/bse0470099 (2010).
41. Ashkenazi, A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19, 325-331, doi: 10.1016/j.cytogfr.2008.04.001 (2008).
42. Santos-Silva, M. C., Freitas, M. S. & Assreuy, J. Involvement of NF-kappaB and glutathione in cytotoxic effects of nitric oxide and taxol on human leukemia cells. Leuk Res 30, 145-152, doi: 10.1016/j.leukres.2005.06.021 (2006).
43. Sultana, H. et al. Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann Oncol 14, 214-219 (2003).
44. Ikeguchi, M., Nakamura, S. & Kaibara, N. Quantitative analysis of expression levels of bax, bcl-2, and survivin in cancer cells during cisplatin treatment. Oncol Rep 9, 1121-1126 (2002).
45. Cummings, B. S. & Schnellmann, R. G. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 302, 8-17 (2002).
46. Niu, D. G. et al. Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer. Oncotarget 6, 3963-3976 (2015).
47. Ge, Z. H. et al. Morphine improved the antitumor effects on MCF-7 cells in combination with 5-Fluorouracil. Biomed Pharmacother 68, 299-305, doi: 10.1016/j.biopha.2013.09.006 (2014).
48. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257, doi: 10.1038/35025220 (2000).
49. Singleton, P. A., Mirzapoiazova, T., Hasina, R., Salgia, R. & Moss, J. Increased mu-opioid receptor expression in metastatic lung cancer. British journal of anaesthesia 113 Suppl 1, i103-108, doi: 10.1093/bja/aeu165 (2014).
50. Zylla, D. et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer 119, 4103-4110, doi: 10.1002/cncr.28345 (2013).
51. Nguyen, J. et al. Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer. British journal of anaesthesia 113 Suppl 1, i4-13, doi: 10.1093/bja/aeu090 (2014).
52. Cata, J. P. et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer medicine 3, 900-908, doi: 10.1002/cam4.236 (2014).
53. Maher, D. P. et al. Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: a retrospective analysis. British journal of anaesthesia 113 Suppl 1, i88-94, doi: 10.1093/bja/aeu192 (2014).
54. Zylla, D., Kuskowski, M. A., Gupta, K. & Gupta, P. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. British journal of anaesthesia, doi: 10.1093/bja/aeu351 (2014).
55. Sasamura, T. et al. Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. Eur J Pharmacol 441, 185-191 (2002).
56. Harimaya, Y. et al. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer letters 187, 121-127 (2002).
57. Koodie, L., Ramakrishnan, S. & Roy, S. Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway. The American journal of pathology 177, 984-997, doi: 10.2353/ajpath.2010.090621 (2010).
58. Zong, J. & Pollack, G. M. Morphine antinociception is enhanced in mdr1a gene-deficient mice. Pharmaceutical research 17, 749-753 (2000).
59. Ornberg, R. L. Proliferation and apoptosis measurements by color image analysis based on differential absorption. J Histochem Cytochem 49, 1059-1060 (2001).